Su2ura ESD Closure Pilot Study

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChinese University of Hong Kong

About this trial

This study is a single-center, prospective, single-arm, non-blinded first-in-human (FIH) early feasibility study intended to evaluate the short-term safety and technical feasibility of closure of gastric post-ESD defects using a novel through-the-scope full-thickness endoscopic suturing system in initial human use.

The subjects shall be patients scheduled to undergo ESD for gastric epithelial lesions at the study site (Prince of Wales Hospital) in Hong Kong who meet the eligibility criteria for this study and from whom written informed consent has been obtained. For the gastric defects created after completion of ESD, closure will be attempted using the study device, and its safety, technical success, and early postoperative maintenance of closure will be evaluated.

The target sample size of this study shall be 5 cases, and no control group shall be established. No comparison with existing defect closure techniques or verification of superiority will be performed. From the viewpoint of patient protection, comparatively controllable gastric post-ESD defects are selected as the entry model, and the safety signal and basic technical success of this device in its initial human use will be evaluated descriptively.

The device specifications used in this study shall remain fixed throughout the study period. During the registration period of the initial cohort of 5 cases, no major changes shall be made to the device itself, accessory equipment, procedural concept, or primary evaluation methods. If device improvement or procedural modification becomes necessary during the study, it shall be handled separately from this initial cohort after obtaining approval from the ethics committee and other relevant authorities, as necessary.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years or older

Patients scheduled to undergo gastric ESD for gastric epithelial lesions

Patients who have received sufficient explanation of this study and from whom written informed consent has been obtained by their own free will

Patients judged by the principal investigator or sub-investigator to be appropriate for participation in this study

Disqualifiers

Perforation cases requiring emergency closure

Cases with severe coagulation abnormalities, bleeding tendency, or other serious systemic conditions, in whom participation in the study is judged to be inappropriate

Cases who are pregnant or may be pregnant

Cases in whom obtaining consent for this study is difficult, including minor patients

Trial design

Design model

Single group

Treatments tested in this trial

  • Su2ura® GI system

    Device

    The Su2ura® O System is a sterile single-use system intended for endoscopic full-thickness approximation of soft tissue through commonly used endoscopic working channels in both the upper and lower gastrointestinal tract. The system comprises of 3 sterile single-use parts; (1) a flexible endoscopic suturing device (Su2ura® O Device), (2) magazine pre-loaded with up to 6 threaded (0.30mm UHMWPE Braided Cord) nitinol T-Anchors and (3) a suture lock and thread cutting mechanism (Su2ura® Knot Device); the system is planned to be used through a commonly used endoscopic working channels. Each anchor is deployed by a single trigger operation. The sutures are aimed to be 'full-thickness' and are achieved using threaded nitinol T-anchors with a reduced friction mechanism, which enables fast tightening. The sutures are designed to be widely used by any interventional endoscopists in all endoscopic suites for procedures performed in both the upper and lower gastrointestinal tract.

Treatment groups

5 Participants
are divided into 1 treatment group
Group A: Su2ura® GI System GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Incidence of device-related adverse events

The primary endpoint shall be the incidence of device-related adverse events and serious adverse events occurring during the procedure or within 30 days postoperatively.

Time frame
30 days

Secondary outcomes

1

Technical success

The proportion of cases in which the planned defect closure procedure could be performed using the study device according to the intended procedure.

Time frame
1 day
2

Complete closure at the end of the procedure

The proportion of cases in which complete closure was endoscopically achieved at the end of the procedure.

Time frame
1 day
3

Closure procedure time

The net time from the start of closure manipulation using the study device until completion of closure or termination of the procedure.

Time frame
1 day
4

Number of anchors / suturing elements used

The number of anchors and locks or suturing elements required for closure.

Time frame
1 day

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: